|IP||1-2 μL/mg of lysate|
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-LRPAP1 mouse monoclonal antibody at 1:500 dilution
Lane A: U87-MG Whole Cell Lysate
Lane B: A549 Whole Cell LysateLysates/proteins at 30 μg per lane.
Goat Anti-Mouse IgG H&L (Dylight800) at 1/15000 dilution.Developed using the Odyssey technique.
Performed under reducing conditions.Predicted band size:41 kDa
Observed band size:41 kDa
LRPAP1 was immunoprecipitated using:
Lane A:0.5 mg 293T Whole Cell Lysate0.5 µL anti-LRPAP1 mouse monoclonal antibody and 15 μl of 50 % Protein G agarose.Primary antibody:
Anti-LRPAP1 mouse monoclonal antibody,at 1:1000 dilutionSecondary antibody:
Dylight 800-labeled antibody to Mouse IgG (H+L), at 1:7500 dilutionDeveloped using the odssey technique.
Performed under reducing conditions.Predicted band size: 41 kDa
Observed band size: 41 kDa
Receptor-associated protein (RAP) is a molecular chaperone for low density lipoprotein receptor-related protein (LRP), which plays a key role in cholesterol metabolism. The lipoprotein receptor-related protein (LRP) is an endocytic receptor for several ligands, such as alpha2-macroglobulin (alpha2 M) and apolipoprotein E. LRP is involved in the clearance of lipids from the bloodstream and is expressed in the atherosclerotic plaque. The LRP-associated protein (LRPAP in humans, RAP in mice) acts as a chaperone protein, stabilizing the nascent LRP peptide in the endoplasmic reticulum and Golgi complex. Alpha-2-macroglobulin receptor-associated protein, also known as low density lipoprotein receptor-related protein-associated protein 1, RAP and LRPAP1, is a 39 kDa protein and a member of the alpha-2-MRAP family. It is a receptor antagonist that interacts with several members of the low density lipoprotein (LDL) receptor gene family. Upon binding to these receptors, LRPAP1 inhibits all ligand interactions with the receptors. LRPAP1 is present on cell surface forming a complex with the alpha-2-macroglobulin receptor heavy and light chains. It binds with LRP1B and the binding is followed by internalization and degradation. LRPAP1 interacts with LRP1/alpha-2-macroglobulin receptor and LRP2 (previously called glycoprotein 330), and may be involved in the pathogenesis of membrane glomerular nephritis. LRPAP1 together with LRP2 forms the Heymann nephritis antigenic complex. LRP2 is expressed in epithelial cells of the thyroid, where it can serve as a receptor for the protein thyroglobulin. Intron 5 insertion/deletion polymorphism of RAP gene (LRPAP1) has been implicated in other diseases sharing etiology with gallstone disease (GSD). The LRPAP1 insertion/deletion polymorphism influences cholesterol homeostasis and may confer risk for gallstone disease and gallbladder carcinoma (GBC) incidence usually parallels with the prevalence of cholelithiosis. The genetic variations at the LRPAP1 locus may modulate Alzheimer disease (AD) phenotype beyond risk for disease. In addition, the variation at the LRPAP1 gene could contribute to the risk of developing an early episode of myocardial infarction (MI).
|Product Description||Host||Clonality||Application||Catalog# (PDF)|